Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
| 1.6 | |
| 1.6 | |
| - | |
| 1.6 | |
| 1.6 | |
| 1.05-3.2 | |
| 3 479 M | |
| 2 126 M | |
| 840 M | |
| -0.0231 | |
| 0.988 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Amidst a mixed landscape for global markets, Hong Kong's Hang Seng Index has shown resilience with a modest gain of 0.46% in a holiday-shortened week, reflecting nuanced investor sentiment towards the...
Amidst a backdrop of fluctuating global markets, the Hong Kong stock market presents intriguing opportunities, evidenced by its recent modest gains. As investors seek value in a landscape marked by mi...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
